nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulindac—osteoarthritis—Prednisone—systemic scleroderma	0.518	1	CpDpCtD
Sulindac—SLC22A6—Captopril—systemic scleroderma	0.0475	0.201	CbGbCtD
Sulindac—ALB—Captopril—systemic scleroderma	0.0405	0.171	CbGbCtD
Sulindac—CYP1A2—Pentoxifylline—systemic scleroderma	0.0324	0.137	CbGbCtD
Sulindac—ALB—Mycophenolate mofetil—systemic scleroderma	0.0319	0.135	CbGbCtD
Sulindac—CYP1A2—Leflunomide—systemic scleroderma	0.0309	0.131	CbGbCtD
Sulindac—ALB—Prednisone—systemic scleroderma	0.0255	0.108	CbGbCtD
Sulindac—SLC22A6—Methotrexate—systemic scleroderma	0.015	0.0635	CbGbCtD
Sulindac—ALB—Methotrexate—systemic scleroderma	0.0128	0.0541	CbGbCtD
Sulindac—MAPK3—artery—systemic scleroderma	0.00436	0.0849	CbGeAlD
Sulindac—MAPK3—endothelium—systemic scleroderma	0.00368	0.0717	CbGeAlD
Sulindac—MAPK3—blood vessel—systemic scleroderma	0.0034	0.0661	CbGeAlD
Sulindac—PTGDR2—tendon—systemic scleroderma	0.00311	0.0605	CbGeAlD
Sulindac—PTGS2—skeletal joint—systemic scleroderma	0.00271	0.0527	CbGeAlD
Sulindac—AKR1B1—connective tissue—systemic scleroderma	0.0024	0.0468	CbGeAlD
Sulindac—AKR1B1—smooth muscle tissue—systemic scleroderma	0.0022	0.0428	CbGeAlD
Sulindac—MAPK3—connective tissue—systemic scleroderma	0.00174	0.0339	CbGeAlD
Sulindac—AKR1B1—digestive system—systemic scleroderma	0.00173	0.0338	CbGeAlD
Sulindac—AKR1B1—tendon—systemic scleroderma	0.00165	0.0321	CbGeAlD
Sulindac—MAPK3—smooth muscle tissue—systemic scleroderma	0.00159	0.031	CbGeAlD
Sulindac—MAPK3—skin of body—systemic scleroderma	0.00157	0.0306	CbGeAlD
Sulindac—AKR1B1—lung—systemic scleroderma	0.00145	0.0282	CbGeAlD
Sulindac—PPARD—digestive system—systemic scleroderma	0.00136	0.0266	CbGeAlD
Sulindac—PPARD—tendon—systemic scleroderma	0.0013	0.0253	CbGeAlD
Sulindac—MAPK3—digestive system—systemic scleroderma	0.00126	0.0245	CbGeAlD
Sulindac—MAPK3—tendon—systemic scleroderma	0.0012	0.0233	CbGeAlD
Sulindac—PTGS2—Fluocinonide—Mometasone—systemic scleroderma	0.00119	0.624	CbGdCrCtD
Sulindac—PTGS1—artery—systemic scleroderma	0.00118	0.0231	CbGeAlD
Sulindac—PPARD—lung—systemic scleroderma	0.00114	0.0222	CbGeAlD
Sulindac—PTGS2—artery—systemic scleroderma	0.00113	0.022	CbGeAlD
Sulindac—MAPK3—lung—systemic scleroderma	0.00105	0.0204	CbGeAlD
Sulindac—PTGS1—endothelium—systemic scleroderma	0.001	0.0195	CbGeAlD
Sulindac—PTGS2—endothelium—systemic scleroderma	0.000956	0.0186	CbGeAlD
Sulindac—PTGS1—blood vessel—systemic scleroderma	0.000923	0.018	CbGeAlD
Sulindac—PTGS2—blood vessel—systemic scleroderma	0.000882	0.0172	CbGeAlD
Sulindac—PTGS2—Fluticasone Propionate—Mometasone—systemic scleroderma	0.000716	0.376	CbGdCrCtD
Sulindac—CYP1A1—skin of body—systemic scleroderma	0.000486	0.00947	CbGeAlD
Sulindac—PTGS1—connective tissue—systemic scleroderma	0.000473	0.00921	CbGeAlD
Sulindac—PTGS2—connective tissue—systemic scleroderma	0.000452	0.0088	CbGeAlD
Sulindac—PTGS1—smooth muscle tissue—systemic scleroderma	0.000433	0.00843	CbGeAlD
Sulindac—PTGS1—skin of body—systemic scleroderma	0.000427	0.00832	CbGeAlD
Sulindac—PTGS2—smooth muscle tissue—systemic scleroderma	0.000414	0.00805	CbGeAlD
Sulindac—PTGS2—skin of body—systemic scleroderma	0.000408	0.00795	CbGeAlD
Sulindac—CYP1A2—digestive system—systemic scleroderma	0.000394	0.00768	CbGeAlD
Sulindac—CYP1A1—digestive system—systemic scleroderma	0.000389	0.00757	CbGeAlD
Sulindac—PTGS1—digestive system—systemic scleroderma	0.000342	0.00665	CbGeAlD
Sulindac—CYP1A2—lung—systemic scleroderma	0.000329	0.00641	CbGeAlD
Sulindac—PTGS2—digestive system—systemic scleroderma	0.000327	0.00636	CbGeAlD
Sulindac—PTGS1—tendon—systemic scleroderma	0.000325	0.00633	CbGeAlD
Sulindac—CYP1A1—lung—systemic scleroderma	0.000325	0.00632	CbGeAlD
Sulindac—PTGS2—tendon—systemic scleroderma	0.000311	0.00605	CbGeAlD
Sulindac—PTGS1—lung—systemic scleroderma	0.000285	0.00556	CbGeAlD
Sulindac—PTGS2—lung—systemic scleroderma	0.000273	0.00531	CbGeAlD
Sulindac—MAPK3—Endothelins—EDN1—systemic scleroderma	0.000254	0.00543	CbGpPWpGaD
Sulindac—MAPK3—Toll Like Receptor 4 (TLR4) Cascade—ITGAM—systemic scleroderma	0.000251	0.00536	CbGpPWpGaD
Sulindac—CYP1A1—Melatonin metabolism and effects—EDN1—systemic scleroderma	0.000249	0.00533	CbGpPWpGaD
Sulindac—PTGDR2—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.000246	0.00525	CbGpPWpGaD
Sulindac—MAPK3—TWEAK Signaling Pathway—CCL2—systemic scleroderma	0.00024	0.00513	CbGpPWpGaD
Sulindac—ALB—Folate Metabolism—CSF1—systemic scleroderma	0.000238	0.00509	CbGpPWpGaD
Sulindac—MAPK3—Regulation of toll-like receptor signaling pathway—IRF5—systemic scleroderma	0.000237	0.00506	CbGpPWpGaD
Sulindac—MAPK3—Mitotic M-M/G1 phases—CENPC—systemic scleroderma	0.000236	0.00504	CbGpPWpGaD
Sulindac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CTLA4—systemic scleroderma	0.000231	0.00494	CbGpPWpGaD
Sulindac—MAPK3—PDGFR-beta signaling pathway—BLK—systemic scleroderma	0.000228	0.00487	CbGpPWpGaD
Sulindac—MAPK3—Regulation of Actin Cytoskeleton—CSK—systemic scleroderma	0.000228	0.00486	CbGpPWpGaD
Sulindac—MAPK3—Toll-Like Receptors Cascades—ITGAM—systemic scleroderma	0.000224	0.00478	CbGpPWpGaD
Sulindac—PTGS2—C-MYB transcription factor network—COL1A2—systemic scleroderma	0.000222	0.00474	CbGpPWpGaD
Sulindac—MAPK3—Osteopontin-mediated events—MMP9—systemic scleroderma	0.000219	0.00468	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—TNFSF13—systemic scleroderma	0.000215	0.0046	CbGpPWpGaD
Sulindac—MAPK3—Endothelins—MMP1—systemic scleroderma	0.000214	0.00456	CbGpPWpGaD
Sulindac—MAPK3—Regulation of toll-like receptor signaling pathway—TNFAIP3—systemic scleroderma	0.000212	0.00453	CbGpPWpGaD
Sulindac—ALB—Platelet degranulation—SELP—systemic scleroderma	0.000212	0.00453	CbGpPWpGaD
Sulindac—MAPK3—Oncostatin M Signaling Pathway—MMP1—systemic scleroderma	0.000208	0.00445	CbGpPWpGaD
Sulindac—MAPK3—ALK1 signaling events—TGFB1—systemic scleroderma	0.000208	0.00444	CbGpPWpGaD
Sulindac—PTGDR2—GPCR downstream signaling—RHOB—systemic scleroderma	0.000207	0.00442	CbGpPWpGaD
Sulindac—MAPK3—Interferon Signaling—IRF5—systemic scleroderma	0.000202	0.00433	CbGpPWpGaD
Sulindac—MAPK3—MicroRNAs in cardiomyocyte hypertrophy—EDN1—systemic scleroderma	0.000202	0.00431	CbGpPWpGaD
Sulindac—ALB—Response to elevated platelet cytosolic Ca2+—SELP—systemic scleroderma	0.000202	0.00431	CbGpPWpGaD
Sulindac—MAPK3—Angiopoietin receptor Tie2-mediated signaling—MMP2—systemic scleroderma	0.000199	0.00425	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR—CSK—systemic scleroderma	0.000197	0.0042	CbGpPWpGaD
Sulindac—MAPK3—Platelet activation, signaling and aggregation—SELP—systemic scleroderma	0.000195	0.00417	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR in Cancer—CSK—systemic scleroderma	0.000195	0.00416	CbGpPWpGaD
Sulindac—AKR1B1—Metabolism—HSPG2—systemic scleroderma	0.000194	0.00415	CbGpPWpGaD
Sulindac—MAPK3—IL-1 signaling pathway—CCL2—systemic scleroderma	0.000194	0.00414	CbGpPWpGaD
Sulindac—MAPK3—Interferon Signaling—IRF8—systemic scleroderma	0.000193	0.00413	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—SELP—systemic scleroderma	0.000192	0.0041	CbGpPWpGaD
Sulindac—MAPK3—TCR Signaling Pathway—IL1A—systemic scleroderma	0.00019	0.00406	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—RHOB—systemic scleroderma	0.000188	0.00401	CbGpPWpGaD
Sulindac—PTGDR2—GPCR ligand binding—EDN1—systemic scleroderma	0.000187	0.00399	CbGpPWpGaD
Sulindac—MAPK3—Angiopoietin receptor Tie2-mediated signaling—NOS3—systemic scleroderma	0.000186	0.00398	CbGpPWpGaD
Sulindac—MAPK3—Syndecan-1-mediated signaling events—MMP9—systemic scleroderma	0.000186	0.00398	CbGpPWpGaD
Sulindac—MAPK3—Platelet activation, signaling and aggregation—RHOB—systemic scleroderma	0.000182	0.00389	CbGpPWpGaD
Sulindac—PPARD—Ectoderm Differentiation—CCL2—systemic scleroderma	0.000182	0.00388	CbGpPWpGaD
Sulindac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—systemic scleroderma	0.00018	0.00384	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—RHOB—systemic scleroderma	0.000179	0.00383	CbGpPWpGaD
Sulindac—MAPK3—IFN-gamma pathway—IL1B—systemic scleroderma	0.000179	0.00382	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000177	0.00378	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle, Mitotic—CENPC—systemic scleroderma	0.000176	0.00377	CbGpPWpGaD
Sulindac—MAPK3—ATF-2 transcription factor network—MMP2—systemic scleroderma	0.000174	0.00372	CbGpPWpGaD
Sulindac—MAPK3—Glucocorticoid receptor regulatory network—MMP1—systemic scleroderma	0.000173	0.00369	CbGpPWpGaD
Sulindac—MAPK3—TWEAK Signaling Pathway—MMP9—systemic scleroderma	0.000172	0.00367	CbGpPWpGaD
Sulindac—MAPK3—Oncostatin M Signaling Pathway—CCL2—systemic scleroderma	0.000169	0.00362	CbGpPWpGaD
Sulindac—PTGDR2—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.000168	0.00359	CbGpPWpGaD
Sulindac—MAPK3—Senescence-Associated Secretory Phenotype (SASP)—IL1A—systemic scleroderma	0.000168	0.00359	CbGpPWpGaD
Sulindac—MAPK3—Platelet activation, signaling and aggregation—CSK—systemic scleroderma	0.000166	0.00355	CbGpPWpGaD
Sulindac—MAPK3—Signaling by Interleukins—IL1A—systemic scleroderma	0.000164	0.00351	CbGpPWpGaD
Sulindac—MAPK3—M Phase—CENPA—systemic scleroderma	0.000163	0.00349	CbGpPWpGaD
Sulindac—MAPK3—Syndecan-2-mediated signaling events—TGFB1—systemic scleroderma	0.00016	0.00342	CbGpPWpGaD
Sulindac—MAPK3—AGE/RAGE pathway—MMP2—systemic scleroderma	0.000159	0.0034	CbGpPWpGaD
Sulindac—CYP1A2—Melatonin metabolism and effects—EDN1—systemic scleroderma	0.000159	0.0034	CbGpPWpGaD
Sulindac—PPARD—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.000158	0.00338	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—CENPC—systemic scleroderma	0.000158	0.00337	CbGpPWpGaD
Sulindac—MAPK3—Syndecan-1-mediated signaling events—TGFB1—systemic scleroderma	0.000153	0.00328	CbGpPWpGaD
Sulindac—MAPK3—Spinal Cord Injury—IL1A—systemic scleroderma	0.000153	0.00327	CbGpPWpGaD
Sulindac—MAPK3—Mitotic M-M/G1 phases—CENPA—systemic scleroderma	0.00015	0.0032	CbGpPWpGaD
Sulindac—MAPK3—AGE/RAGE pathway—NOS3—systemic scleroderma	0.000149	0.00319	CbGpPWpGaD
Sulindac—AKR1B1—Metabolism—CTGF—systemic scleroderma	0.000147	0.00315	CbGpPWpGaD
Sulindac—MAPK3—IL-1 signaling pathway—IL1B—systemic scleroderma	0.000147	0.00314	CbGpPWpGaD
Sulindac—MAPK3—Signaling events mediated by VEGFR1 and VEGFR2—NOS3—systemic scleroderma	0.000146	0.00311	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—SMAD7—systemic scleroderma	0.000144	0.00307	CbGpPWpGaD
Sulindac—PPARD—Generic Transcription Pathway—CTGF—systemic scleroderma	0.000142	0.00304	CbGpPWpGaD
Sulindac—MAPK3—FGF signaling pathway—MMP9—systemic scleroderma	0.00014	0.003	CbGpPWpGaD
Sulindac—MAPK3—Interleukin-11 Signaling Pathway—TGFB1—systemic scleroderma	0.000136	0.00291	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—IRF5—systemic scleroderma	0.000135	0.00289	CbGpPWpGaD
Sulindac—MAPK3—Leptin signaling pathway—NOS3—systemic scleroderma	0.000135	0.00288	CbGpPWpGaD
Sulindac—Pancreatitis—Prednisone—systemic scleroderma	0.000135	0.000922	CcSEcCtD
Sulindac—Vomiting—Mometasone—systemic scleroderma	0.000134	0.000921	CcSEcCtD
Sulindac—MAPK3—Axon guidance—RHOB—systemic scleroderma	0.000134	0.00287	CbGpPWpGaD
Sulindac—Sweating increased—Prednisone—systemic scleroderma	0.000134	0.000916	CcSEcCtD
Sulindac—Feeling abnormal—Azathioprine—systemic scleroderma	0.000133	0.000915	CcSEcCtD
Sulindac—Rash—Mometasone—systemic scleroderma	0.000133	0.000913	CcSEcCtD
Sulindac—Asthenia—Captopril—systemic scleroderma	0.000133	0.000913	CcSEcCtD
Sulindac—Dermatitis—Mometasone—systemic scleroderma	0.000133	0.000912	CcSEcCtD
Sulindac—Decreased appetite—Leflunomide—systemic scleroderma	0.000133	0.000911	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000133	0.000911	CcSEcCtD
Sulindac—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000132	0.000908	CcSEcCtD
Sulindac—Headache—Mometasone—systemic scleroderma	0.000132	0.000907	CcSEcCtD
Sulindac—Insomnia—Mycophenolic acid—systemic scleroderma	0.000132	0.000904	CcSEcCtD
Sulindac—Fatigue—Leflunomide—systemic scleroderma	0.000132	0.000904	CcSEcCtD
Sulindac—Anaphylactic shock—Lisinopril—systemic scleroderma	0.000131	0.000901	CcSEcCtD
Sulindac—Oedema—Lisinopril—systemic scleroderma	0.000131	0.000901	CcSEcCtD
Sulindac—Pruritus—Captopril—systemic scleroderma	0.000131	0.0009	CcSEcCtD
Sulindac—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.000131	0.000898	CcSEcCtD
Sulindac—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	0.000131	0.000897	CcSEcCtD
Sulindac—Constipation—Leflunomide—systemic scleroderma	0.000131	0.000896	CcSEcCtD
Sulindac—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.00013	0.000894	CcSEcCtD
Sulindac—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.00013	0.000892	CcSEcCtD
Sulindac—Somnolence—Mycophenolic acid—systemic scleroderma	0.00013	0.000889	CcSEcCtD
Sulindac—Shock—Lisinopril—systemic scleroderma	0.000129	0.000886	CcSEcCtD
Sulindac—MAPK3—Cytokine Signaling in Immune system—IRF8—systemic scleroderma	0.000129	0.00276	CbGpPWpGaD
Sulindac—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.000129	0.000884	CcSEcCtD
Sulindac—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000129	0.000882	CcSEcCtD
Sulindac—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000128	0.00088	CcSEcCtD
Sulindac—Neutropenia—Prednisone—systemic scleroderma	0.000128	0.00088	CcSEcCtD
Sulindac—MAPK3—TNF alpha Signaling Pathway—CCL2—systemic scleroderma	0.000128	0.00274	CbGpPWpGaD
Sulindac—Tachycardia—Lisinopril—systemic scleroderma	0.000128	0.000879	CcSEcCtD
Sulindac—Body temperature increased—Azathioprine—systemic scleroderma	0.000128	0.000877	CcSEcCtD
Sulindac—PTGDR2—GPCR ligand binding—CCL2—systemic scleroderma	0.000128	0.00273	CbGpPWpGaD
Sulindac—Malaise—Mycophenolate mofetil—systemic scleroderma	0.000127	0.000872	CcSEcCtD
Sulindac—Hyperhidrosis—Lisinopril—systemic scleroderma	0.000127	0.000871	CcSEcCtD
Sulindac—Diarrhoea—Captopril—systemic scleroderma	0.000127	0.00087	CcSEcCtD
Sulindac—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000127	0.000869	CcSEcCtD
Sulindac—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.000127	0.000869	CcSEcCtD
Sulindac—Syncope—Mycophenolate mofetil—systemic scleroderma	0.000126	0.000867	CcSEcCtD
Sulindac—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000126	0.000866	CcSEcCtD
Sulindac—Feeling abnormal—Leflunomide—systemic scleroderma	0.000126	0.000864	CcSEcCtD
Sulindac—Fatigue—Mycophenolic acid—systemic scleroderma	0.000126	0.000862	CcSEcCtD
Sulindac—Nausea—Mometasone—systemic scleroderma	0.000125	0.00086	CcSEcCtD
Sulindac—Anorexia—Lisinopril—systemic scleroderma	0.000125	0.000859	CcSEcCtD
Sulindac—MAPK3—IL-3 Signaling Pathway—TGFB1—systemic scleroderma	0.000125	0.00267	CbGpPWpGaD
Sulindac—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000125	0.000857	CcSEcCtD
Sulindac—Constipation—Mycophenolic acid—systemic scleroderma	0.000125	0.000855	CcSEcCtD
Sulindac—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000125	0.000855	CcSEcCtD
Sulindac—PPARD—Gene Expression—SMAD7—systemic scleroderma	0.000124	0.00265	CbGpPWpGaD
Sulindac—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000124	0.00085	CcSEcCtD
Sulindac—Hyperglycaemia—Prednisone—systemic scleroderma	0.000124	0.000849	CcSEcCtD
Sulindac—Hypotension—Lisinopril—systemic scleroderma	0.000123	0.000842	CcSEcCtD
Sulindac—Dizziness—Captopril—systemic scleroderma	0.000123	0.000841	CcSEcCtD
Sulindac—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000122	0.000838	CcSEcCtD
Sulindac—Depression—Prednisone—systemic scleroderma	0.000122	0.000836	CcSEcCtD
Sulindac—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000122	0.000835	CcSEcCtD
Sulindac—Urticaria—Leflunomide—systemic scleroderma	0.000121	0.000833	CcSEcCtD
Sulindac—Body temperature increased—Leflunomide—systemic scleroderma	0.000121	0.000829	CcSEcCtD
Sulindac—MAPK3—Interferon Signaling—HLA-DQB1—systemic scleroderma	0.000121	0.00258	CbGpPWpGaD
Sulindac—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.00012	0.000824	CcSEcCtD
Sulindac—CYP1A1—PPARA activates gene expression—CTGF—systemic scleroderma	0.00012	0.00257	CbGpPWpGaD
Sulindac—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.00012	0.000823	CcSEcCtD
Sulindac—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.00012	0.000823	CcSEcCtD
Sulindac—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.00012	0.000823	CcSEcCtD
Sulindac—Neuropathy peripheral—Prednisone—systemic scleroderma	0.00012	0.000822	CcSEcCtD
Sulindac—PPARD—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	0.00012	0.00256	CbGpPWpGaD
Sulindac—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.00012	0.000821	CcSEcCtD
Sulindac—MAPK3—AGE/RAGE pathway—MMP9—systemic scleroderma	0.00012	0.00256	CbGpPWpGaD
Sulindac—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.000119	0.000819	CcSEcCtD
Sulindac—Hypersensitivity—Azathioprine—systemic scleroderma	0.000119	0.000818	CcSEcCtD
Sulindac—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000119	0.000818	CcSEcCtD
Sulindac—Insomnia—Lisinopril—systemic scleroderma	0.000119	0.000815	CcSEcCtD
Sulindac—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000119	0.000813	CcSEcCtD
Sulindac—Paraesthesia—Lisinopril—systemic scleroderma	0.000118	0.000809	CcSEcCtD
Sulindac—Vomiting—Captopril—systemic scleroderma	0.000118	0.000809	CcSEcCtD
Sulindac—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CTGF—systemic scleroderma	0.000118	0.00251	CbGpPWpGaD
Sulindac—Dyspnoea—Lisinopril—systemic scleroderma	0.000117	0.000803	CcSEcCtD
Sulindac—Rash—Captopril—systemic scleroderma	0.000117	0.000802	CcSEcCtD
Sulindac—Dermatitis—Captopril—systemic scleroderma	0.000117	0.000801	CcSEcCtD
Sulindac—Somnolence—Lisinopril—systemic scleroderma	0.000117	0.000801	CcSEcCtD
Sulindac—Headache—Captopril—systemic scleroderma	0.000116	0.000797	CcSEcCtD
Sulindac—MAPK3—TGF-beta Receptor Signaling—TGFB1—systemic scleroderma	0.000116	0.00247	CbGpPWpGaD
Sulindac—Dyspepsia—Lisinopril—systemic scleroderma	0.000116	0.000793	CcSEcCtD
Sulindac—PPARD—Gene Expression—TNFSF13—systemic scleroderma	0.000115	0.00246	CbGpPWpGaD
Sulindac—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000115	0.000791	CcSEcCtD
Sulindac—MAPK3—MAPK Signaling Pathway—IL1A—systemic scleroderma	0.000115	0.00246	CbGpPWpGaD
Sulindac—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000115	0.000789	CcSEcCtD
Sulindac—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000115	0.000789	CcSEcCtD
Sulindac—MAPK3—Leptin signaling pathway—IL1B—systemic scleroderma	0.000115	0.00245	CbGpPWpGaD
Sulindac—MAPK3—Corticotropin-releasing hormone—NOS3—systemic scleroderma	0.000114	0.00244	CbGpPWpGaD
Sulindac—Decreased appetite—Lisinopril—systemic scleroderma	0.000114	0.000783	CcSEcCtD
Sulindac—MAPK3—Cardiac Hypertrophic Response—TGFB1—systemic scleroderma	0.000114	0.00244	CbGpPWpGaD
Sulindac—Eosinophilia—Methotrexate—systemic scleroderma	0.000114	0.000778	CcSEcCtD
Sulindac—Fatigue—Lisinopril—systemic scleroderma	0.000113	0.000777	CcSEcCtD
Sulindac—Shock—Mycophenolate mofetil—systemic scleroderma	0.000113	0.000776	CcSEcCtD
Sulindac—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000113	0.000773	CcSEcCtD
Sulindac—Hypersensitivity—Leflunomide—systemic scleroderma	0.000113	0.000772	CcSEcCtD
Sulindac—Pancreatitis—Methotrexate—systemic scleroderma	0.000112	0.000771	CcSEcCtD
Sulindac—Constipation—Lisinopril—systemic scleroderma	0.000112	0.00077	CcSEcCtD
Sulindac—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000112	0.00077	CcSEcCtD
Sulindac—PPARD—Adipogenesis—TGFB1—systemic scleroderma	0.000112	0.0024	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle, Mitotic—CENPA—systemic scleroderma	0.000112	0.00239	CbGpPWpGaD
Sulindac—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000111	0.000763	CcSEcCtD
Sulindac—PTGDR2—Signaling Pathways—RHOB—systemic scleroderma	0.000111	0.00237	CbGpPWpGaD
Sulindac—Diarrhoea—Azathioprine—systemic scleroderma	0.000111	0.000759	CcSEcCtD
Sulindac—Nausea—Captopril—systemic scleroderma	0.00011	0.000755	CcSEcCtD
Sulindac—MAPK3—Alzheimers Disease—IL1B—systemic scleroderma	0.00011	0.00235	CbGpPWpGaD
Sulindac—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.00011	0.000752	CcSEcCtD
Sulindac—Asthenia—Leflunomide—systemic scleroderma	0.00011	0.000752	CcSEcCtD
Sulindac—Pancytopenia—Methotrexate—systemic scleroderma	0.000109	0.000747	CcSEcCtD
Sulindac—Feeling abnormal—Lisinopril—systemic scleroderma	0.000108	0.000742	CcSEcCtD
Sulindac—Pruritus—Leflunomide—systemic scleroderma	0.000108	0.000742	CcSEcCtD
Sulindac—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000108	0.000737	CcSEcCtD
Sulindac—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000107	0.000737	CcSEcCtD
Sulindac—Neutropenia—Methotrexate—systemic scleroderma	0.000107	0.000735	CcSEcCtD
Sulindac—Dysuria—Methotrexate—systemic scleroderma	0.000107	0.000735	CcSEcCtD
Sulindac—Dizziness—Azathioprine—systemic scleroderma	0.000107	0.000734	CcSEcCtD
Sulindac—MAPK3—Cellular Senescence—IL1A—systemic scleroderma	0.000106	0.00227	CbGpPWpGaD
Sulindac—PTGDR2—GPCR downstream signaling—EDN1—systemic scleroderma	0.000106	0.00226	CbGpPWpGaD
Sulindac—MAPK3—Spinal Cord Injury—CCL2—systemic scleroderma	0.000105	0.00225	CbGpPWpGaD
Sulindac—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000105	0.000719	CcSEcCtD
Sulindac—PTGDR2—Signaling Pathways—HSPG2—systemic scleroderma	0.000105	0.00224	CbGpPWpGaD
Sulindac—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.000105	0.000718	CcSEcCtD
Sulindac—Asthenia—Mycophenolic acid—systemic scleroderma	0.000105	0.000717	CcSEcCtD
Sulindac—Diarrhoea—Leflunomide—systemic scleroderma	0.000105	0.000717	CcSEcCtD
Sulindac—Urticaria—Lisinopril—systemic scleroderma	0.000104	0.000716	CcSEcCtD
Sulindac—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000104	0.000714	CcSEcCtD
Sulindac—Body temperature increased—Lisinopril—systemic scleroderma	0.000104	0.000712	CcSEcCtD
Sulindac—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000103	0.000709	CcSEcCtD
Sulindac—Pruritus—Mycophenolic acid—systemic scleroderma	0.000103	0.000707	CcSEcCtD
Sulindac—Vomiting—Azathioprine—systemic scleroderma	0.000103	0.000706	CcSEcCtD
Sulindac—Pneumonia—Methotrexate—systemic scleroderma	0.000103	0.000705	CcSEcCtD
Sulindac—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000103	0.000704	CcSEcCtD
Sulindac—PPARD—NRF2 pathway—TGFB1—systemic scleroderma	0.000102	0.00219	CbGpPWpGaD
Sulindac—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000102	0.000702	CcSEcCtD
Sulindac—Rash—Azathioprine—systemic scleroderma	0.000102	0.0007	CcSEcCtD
Sulindac—Dermatitis—Azathioprine—systemic scleroderma	0.000102	0.000699	CcSEcCtD
Sulindac—Depression—Methotrexate—systemic scleroderma	0.000102	0.000699	CcSEcCtD
Sulindac—Flushing—Prednisone—systemic scleroderma	0.000102	0.000699	CcSEcCtD
Sulindac—Headache—Azathioprine—systemic scleroderma	0.000101	0.000695	CcSEcCtD
Sulindac—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.000101	0.000695	CcSEcCtD
Sulindac—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000101	0.000695	CcSEcCtD
Sulindac—MAPK3—VEGFA-VEGFR2 Pathway—NOS3—systemic scleroderma	0.000101	0.00216	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—CSK—systemic scleroderma	0.000101	0.00216	CbGpPWpGaD
Sulindac—Dizziness—Leflunomide—systemic scleroderma	0.000101	0.000693	CcSEcCtD
Sulindac—MAPK3—Hemostasis—SELP—systemic scleroderma	0.000101	0.00215	CbGpPWpGaD
Sulindac—Renal failure—Methotrexate—systemic scleroderma	0.000101	0.000689	CcSEcCtD
Sulindac—MAPK3—Cell Cycle—CENPA—systemic scleroderma	0.0001	0.00214	CbGpPWpGaD
Sulindac—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.0001	0.000686	CcSEcCtD
Sulindac—Diarrhoea—Mycophenolic acid—systemic scleroderma	9.98e-05	0.000684	CcSEcCtD
Sulindac—Stomatitis—Methotrexate—systemic scleroderma	9.97e-05	0.000683	CcSEcCtD
Sulindac—PTGS1—Selenium Micronutrient Network—CCL2—systemic scleroderma	9.96e-05	0.00213	CbGpPWpGaD
Sulindac—Conjunctivitis—Methotrexate—systemic scleroderma	9.94e-05	0.000681	CcSEcCtD
Sulindac—MAPK3—TCR Signaling Pathway—IL1B—systemic scleroderma	9.9e-05	0.00212	CbGpPWpGaD
Sulindac—ALB—Vitamin B12 Metabolism—CCL2—systemic scleroderma	9.89e-05	0.00211	CbGpPWpGaD
Sulindac—Constipation—Mycophenolate mofetil—systemic scleroderma	9.84e-05	0.000675	CcSEcCtD
Sulindac—Arrhythmia—Prednisone—systemic scleroderma	9.81e-05	0.000673	CcSEcCtD
Sulindac—Sweating—Methotrexate—systemic scleroderma	9.8e-05	0.000672	CcSEcCtD
Sulindac—Haematuria—Methotrexate—systemic scleroderma	9.75e-05	0.000668	CcSEcCtD
Sulindac—Vomiting—Leflunomide—systemic scleroderma	9.72e-05	0.000666	CcSEcCtD
Sulindac—Alopecia—Prednisone—systemic scleroderma	9.7e-05	0.000665	CcSEcCtD
Sulindac—Hypersensitivity—Lisinopril—systemic scleroderma	9.68e-05	0.000664	CcSEcCtD
Sulindac—Dizziness—Mycophenolic acid—systemic scleroderma	9.65e-05	0.000661	CcSEcCtD
Sulindac—Epistaxis—Methotrexate—systemic scleroderma	9.64e-05	0.000661	CcSEcCtD
Sulindac—Rash—Leflunomide—systemic scleroderma	9.64e-05	0.000661	CcSEcCtD
Sulindac—Dermatitis—Leflunomide—systemic scleroderma	9.63e-05	0.00066	CcSEcCtD
Sulindac—MAPK3—Regulation of Telomerase—TGFB1—systemic scleroderma	9.63e-05	0.00206	CbGpPWpGaD
Sulindac—Nausea—Azathioprine—systemic scleroderma	9.62e-05	0.000659	CcSEcCtD
Sulindac—PTGDR2—Signaling by GPCR—EDN1—systemic scleroderma	9.59e-05	0.00205	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—RHOB—systemic scleroderma	9.58e-05	0.00205	CbGpPWpGaD
Sulindac—Headache—Leflunomide—systemic scleroderma	9.58e-05	0.000657	CcSEcCtD
Sulindac—MAPK3—Signaling by VEGF—NOS3—systemic scleroderma	9.56e-05	0.00204	CbGpPWpGaD
Sulindac—Agranulocytosis—Methotrexate—systemic scleroderma	9.54e-05	0.000654	CcSEcCtD
Sulindac—MAPK3—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—systemic scleroderma	9.52e-05	0.00203	CbGpPWpGaD
Sulindac—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	9.49e-05	0.00065	CcSEcCtD
Sulindac—Asthenia—Lisinopril—systemic scleroderma	9.43e-05	0.000646	CcSEcCtD
Sulindac—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	9.41e-05	0.000645	CcSEcCtD
Sulindac—MAPK3—Hemostasis—RHOB—systemic scleroderma	9.4e-05	0.00201	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—SELP—systemic scleroderma	9.4e-05	0.00201	CbGpPWpGaD
Sulindac—Pruritus—Lisinopril—systemic scleroderma	9.29e-05	0.000637	CcSEcCtD
Sulindac—Vomiting—Mycophenolic acid—systemic scleroderma	9.27e-05	0.000636	CcSEcCtD
Sulindac—Rash—Mycophenolic acid—systemic scleroderma	9.2e-05	0.000631	CcSEcCtD
Sulindac—Dermatitis—Mycophenolic acid—systemic scleroderma	9.19e-05	0.00063	CcSEcCtD
Sulindac—Hepatitis—Methotrexate—systemic scleroderma	9.18e-05	0.000629	CcSEcCtD
Sulindac—Urticaria—Mycophenolate mofetil—systemic scleroderma	9.14e-05	0.000627	CcSEcCtD
Sulindac—Headache—Mycophenolic acid—systemic scleroderma	9.14e-05	0.000626	CcSEcCtD
Sulindac—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	9.1e-05	0.000624	CcSEcCtD
Sulindac—PTGS2—Spinal Cord Injury—IL1A—systemic scleroderma	9.09e-05	0.00194	CbGpPWpGaD
Sulindac—Nausea—Leflunomide—systemic scleroderma	9.08e-05	0.000623	CcSEcCtD
Sulindac—Vision blurred—Prednisone—systemic scleroderma	9.01e-05	0.000618	CcSEcCtD
Sulindac—Diarrhoea—Lisinopril—systemic scleroderma	8.99e-05	0.000616	CcSEcCtD
Sulindac—MAPK3—Toll-like Receptor Signaling Pathway—IL1B—systemic scleroderma	8.96e-05	0.00191	CbGpPWpGaD
Sulindac—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL1B—systemic scleroderma	8.94e-05	0.00191	CbGpPWpGaD
Sulindac—Ill-defined disorder—Prednisone—systemic scleroderma	8.87e-05	0.000608	CcSEcCtD
Sulindac—Visual impairment—Methotrexate—systemic scleroderma	8.85e-05	0.000606	CcSEcCtD
Sulindac—Anaemia—Prednisone—systemic scleroderma	8.84e-05	0.000606	CcSEcCtD
Sulindac—ALB—Platelet activation, signaling and aggregation—RHOB—systemic scleroderma	8.77e-05	0.00187	CbGpPWpGaD
Sulindac—Angioedema—Prednisone—systemic scleroderma	8.74e-05	0.000599	CcSEcCtD
Sulindac—Dizziness—Lisinopril—systemic scleroderma	8.69e-05	0.000596	CcSEcCtD
Sulindac—Erythema multiforme—Methotrexate—systemic scleroderma	8.68e-05	0.000595	CcSEcCtD
Sulindac—Nausea—Mycophenolic acid—systemic scleroderma	8.66e-05	0.000594	CcSEcCtD
Sulindac—Malaise—Prednisone—systemic scleroderma	8.62e-05	0.000591	CcSEcCtD
Sulindac—Vertigo—Prednisone—systemic scleroderma	8.59e-05	0.000589	CcSEcCtD
Sulindac—Syncope—Prednisone—systemic scleroderma	8.57e-05	0.000588	CcSEcCtD
Sulindac—MAPK3—Hemostasis—CSK—systemic scleroderma	8.56e-05	0.00183	CbGpPWpGaD
Sulindac—MAPK3—Signaling by Interleukins—IL1B—systemic scleroderma	8.56e-05	0.00183	CbGpPWpGaD
Sulindac—Tinnitus—Methotrexate—systemic scleroderma	8.56e-05	0.000587	CcSEcCtD
Sulindac—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	8.48e-05	0.000581	CcSEcCtD
Sulindac—Loss of consciousness—Prednisone—systemic scleroderma	8.4e-05	0.000576	CcSEcCtD
Sulindac—Vomiting—Lisinopril—systemic scleroderma	8.35e-05	0.000573	CcSEcCtD
Sulindac—Rash—Lisinopril—systemic scleroderma	8.28e-05	0.000568	CcSEcCtD
Sulindac—Convulsion—Prednisone—systemic scleroderma	8.28e-05	0.000568	CcSEcCtD
Sulindac—Dermatitis—Lisinopril—systemic scleroderma	8.28e-05	0.000567	CcSEcCtD
Sulindac—Asthenia—Mycophenolate mofetil—systemic scleroderma	8.26e-05	0.000566	CcSEcCtD
Sulindac—Hypertension—Prednisone—systemic scleroderma	8.25e-05	0.000566	CcSEcCtD
Sulindac—Chills—Methotrexate—systemic scleroderma	8.24e-05	0.000565	CcSEcCtD
Sulindac—Headache—Lisinopril—systemic scleroderma	8.23e-05	0.000564	CcSEcCtD
Sulindac—Pruritus—Mycophenolate mofetil—systemic scleroderma	8.14e-05	0.000558	CcSEcCtD
Sulindac—Myalgia—Prednisone—systemic scleroderma	8.14e-05	0.000558	CcSEcCtD
Sulindac—Arthralgia—Prednisone—systemic scleroderma	8.14e-05	0.000558	CcSEcCtD
Sulindac—MAPK3—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—systemic scleroderma	8.13e-05	0.00174	CbGpPWpGaD
Sulindac—Alopecia—Methotrexate—systemic scleroderma	8.11e-05	0.000556	CcSEcCtD
Sulindac—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CTGF—systemic scleroderma	8.1e-05	0.00173	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—HLA-DQB1—systemic scleroderma	8.06e-05	0.00172	CbGpPWpGaD
Sulindac—ALB—Folate Metabolism—CCL2—systemic scleroderma	8.05e-05	0.00172	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—ITGAM—systemic scleroderma	8.05e-05	0.00172	CbGpPWpGaD
Sulindac—Discomfort—Prednisone—systemic scleroderma	8.04e-05	0.000551	CcSEcCtD
Sulindac—MAPK3—Cellular responses to stress—IL1A—systemic scleroderma	8.03e-05	0.00171	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—CSK—systemic scleroderma	7.99e-05	0.00171	CbGpPWpGaD
Sulindac—MAPK3—Spinal Cord Injury—IL1B—systemic scleroderma	7.97e-05	0.0017	CbGpPWpGaD
Sulindac—PTGS2—Selenium Micronutrient Network—CCL2—systemic scleroderma	7.9e-05	0.00169	CbGpPWpGaD
Sulindac—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	7.88e-05	0.00054	CcSEcCtD
Sulindac—Dysgeusia—Methotrexate—systemic scleroderma	7.82e-05	0.000536	CcSEcCtD
Sulindac—Nausea—Lisinopril—systemic scleroderma	7.8e-05	0.000535	CcSEcCtD
Sulindac—Anaphylactic shock—Prednisone—systemic scleroderma	7.8e-05	0.000535	CcSEcCtD
Sulindac—Oedema—Prednisone—systemic scleroderma	7.8e-05	0.000535	CcSEcCtD
Sulindac—MAPK3—TCR Signaling Pathway—TGFB1—systemic scleroderma	7.69e-05	0.00164	CbGpPWpGaD
Sulindac—Shock—Prednisone—systemic scleroderma	7.68e-05	0.000526	CcSEcCtD
Sulindac—MAPK3—Cytokine Signaling in Immune system—IL1A—systemic scleroderma	7.66e-05	0.00164	CbGpPWpGaD
Sulindac—Tachycardia—Prednisone—systemic scleroderma	7.62e-05	0.000522	CcSEcCtD
Sulindac—Dizziness—Mycophenolate mofetil—systemic scleroderma	7.61e-05	0.000522	CcSEcCtD
Sulindac—MAPK3—Corticotropin-releasing hormone—TGFB1—systemic scleroderma	7.56e-05	0.00162	CbGpPWpGaD
Sulindac—PTGS1—Selenium Micronutrient Network—IL1B—systemic scleroderma	7.55e-05	0.00161	CbGpPWpGaD
Sulindac—Hyperhidrosis—Prednisone—systemic scleroderma	7.54e-05	0.000517	CcSEcCtD
Sulindac—Vision blurred—Methotrexate—systemic scleroderma	7.53e-05	0.000516	CcSEcCtD
Sulindac—MAPK3—Spinal Cord Injury—MMP9—systemic scleroderma	7.52e-05	0.00161	CbGpPWpGaD
Sulindac—ALB—Vitamin B12 Metabolism—IL1B—systemic scleroderma	7.5e-05	0.0016	CbGpPWpGaD
Sulindac—Anorexia—Prednisone—systemic scleroderma	7.44e-05	0.00051	CcSEcCtD
Sulindac—Ill-defined disorder—Methotrexate—systemic scleroderma	7.41e-05	0.000508	CcSEcCtD
Sulindac—Anaemia—Methotrexate—systemic scleroderma	7.38e-05	0.000506	CcSEcCtD
Sulindac—Vomiting—Mycophenolate mofetil—systemic scleroderma	7.32e-05	0.000502	CcSEcCtD
Sulindac—Rash—Mycophenolate mofetil—systemic scleroderma	7.26e-05	0.000498	CcSEcCtD
Sulindac—Dermatitis—Mycophenolate mofetil—systemic scleroderma	7.25e-05	0.000497	CcSEcCtD
Sulindac—MAPK3—Innate Immune System—CD247—systemic scleroderma	7.24e-05	0.00155	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—ITGAM—systemic scleroderma	7.24e-05	0.00155	CbGpPWpGaD
Sulindac—Headache—Mycophenolate mofetil—systemic scleroderma	7.21e-05	0.000494	CcSEcCtD
Sulindac—Malaise—Methotrexate—systemic scleroderma	7.21e-05	0.000494	CcSEcCtD
Sulindac—Vertigo—Methotrexate—systemic scleroderma	7.18e-05	0.000492	CcSEcCtD
Sulindac—Leukopenia—Methotrexate—systemic scleroderma	7.15e-05	0.00049	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Prednisone—systemic scleroderma	7.11e-05	0.000487	CcSEcCtD
Sulindac—Insomnia—Prednisone—systemic scleroderma	7.06e-05	0.000484	CcSEcCtD
Sulindac—PPARD—Metabolism—HSPG2—systemic scleroderma	7.04e-05	0.0015	CbGpPWpGaD
Sulindac—Paraesthesia—Prednisone—systemic scleroderma	7.01e-05	0.00048	CcSEcCtD
Sulindac—MAPK3—Regulation of toll-like receptor signaling pathway—IL1B—systemic scleroderma	6.99e-05	0.00149	CbGpPWpGaD
Sulindac—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	6.95e-05	0.00148	CbGpPWpGaD
Sulindac—Convulsion—Methotrexate—systemic scleroderma	6.92e-05	0.000475	CcSEcCtD
Sulindac—Dyspepsia—Prednisone—systemic scleroderma	6.87e-05	0.000471	CcSEcCtD
Sulindac—PPARD—Gene Expression—CTGF—systemic scleroderma	6.86e-05	0.00147	CbGpPWpGaD
Sulindac—Nausea—Mycophenolate mofetil—systemic scleroderma	6.84e-05	0.000469	CcSEcCtD
Sulindac—Myalgia—Methotrexate—systemic scleroderma	6.8e-05	0.000466	CcSEcCtD
Sulindac—Arthralgia—Methotrexate—systemic scleroderma	6.8e-05	0.000466	CcSEcCtD
Sulindac—Chest pain—Methotrexate—systemic scleroderma	6.8e-05	0.000466	CcSEcCtD
Sulindac—MAPK3—Innate Immune System—TNFAIP3—systemic scleroderma	6.78e-05	0.00145	CbGpPWpGaD
Sulindac—Decreased appetite—Prednisone—systemic scleroderma	6.78e-05	0.000465	CcSEcCtD
Sulindac—Fatigue—Prednisone—systemic scleroderma	6.73e-05	0.000461	CcSEcCtD
Sulindac—Discomfort—Methotrexate—systemic scleroderma	6.72e-05	0.000461	CcSEcCtD
Sulindac—Constipation—Prednisone—systemic scleroderma	6.67e-05	0.000457	CcSEcCtD
Sulindac—PTGDR2—Signaling by GPCR—CCL2—systemic scleroderma	6.56e-05	0.0014	CbGpPWpGaD
Sulindac—Anaphylactic shock—Methotrexate—systemic scleroderma	6.52e-05	0.000447	CcSEcCtD
Sulindac—MAPK3—Signaling by SCF-KIT—MMP9—systemic scleroderma	6.52e-05	0.00139	CbGpPWpGaD
Sulindac—Feeling abnormal—Prednisone—systemic scleroderma	6.43e-05	0.000441	CcSEcCtD
Sulindac—AKR1B1—Metabolism—NOS3—systemic scleroderma	6.41e-05	0.00137	CbGpPWpGaD
Sulindac—ALB—Selenium Micronutrient Network—CCL2—systemic scleroderma	6.4e-05	0.00137	CbGpPWpGaD
Sulindac—Thrombocytopenia—Methotrexate—systemic scleroderma	6.38e-05	0.000438	CcSEcCtD
Sulindac—Gastrointestinal pain—Prednisone—systemic scleroderma	6.38e-05	0.000437	CcSEcCtD
Sulindac—MAPK3—Gene Expression—SMAD7—systemic scleroderma	6.33e-05	0.00135	CbGpPWpGaD
Sulindac—Hyperhidrosis—Methotrexate—systemic scleroderma	6.3e-05	0.000432	CcSEcCtD
Sulindac—PTGS2—Spinal Cord Injury—CCL2—systemic scleroderma	6.25e-05	0.00134	CbGpPWpGaD
Sulindac—Anorexia—Methotrexate—systemic scleroderma	6.22e-05	0.000426	CcSEcCtD
Sulindac—Urticaria—Prednisone—systemic scleroderma	6.2e-05	0.000425	CcSEcCtD
Sulindac—MAPK3—Spinal Cord Injury—TGFB1—systemic scleroderma	6.2e-05	0.00132	CbGpPWpGaD
Sulindac—Body temperature increased—Prednisone—systemic scleroderma	6.17e-05	0.000423	CcSEcCtD
Sulindac—ALB—Folate Metabolism—IL1B—systemic scleroderma	6.11e-05	0.0013	CbGpPWpGaD
Sulindac—Hypotension—Methotrexate—systemic scleroderma	6.09e-05	0.000418	CcSEcCtD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	6.04e-05	0.00129	CbGpPWpGaD
Sulindac—MAPK3—MAPK Signaling Pathway—IL1B—systemic scleroderma	6.01e-05	0.00128	CbGpPWpGaD
Sulindac—PTGS2—Selenium Micronutrient Network—IL1B—systemic scleroderma	6e-05	0.00128	CbGpPWpGaD
Sulindac—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	5.94e-05	0.000407	CcSEcCtD
Sulindac—Insomnia—Methotrexate—systemic scleroderma	5.9e-05	0.000404	CcSEcCtD
Sulindac—MAPK3—Gene Expression—TNFSF13—systemic scleroderma	5.89e-05	0.00126	CbGpPWpGaD
Sulindac—MAPK3—Disease—SMAD7—systemic scleroderma	5.88e-05	0.00126	CbGpPWpGaD
Sulindac—Paraesthesia—Methotrexate—systemic scleroderma	5.86e-05	0.000401	CcSEcCtD
Sulindac—Dyspnoea—Methotrexate—systemic scleroderma	5.81e-05	0.000399	CcSEcCtD
Sulindac—Somnolence—Methotrexate—systemic scleroderma	5.8e-05	0.000397	CcSEcCtD
Sulindac—Hypersensitivity—Prednisone—systemic scleroderma	5.75e-05	0.000394	CcSEcCtD
Sulindac—Dyspepsia—Methotrexate—systemic scleroderma	5.74e-05	0.000394	CcSEcCtD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—systemic scleroderma	5.7e-05	0.00122	CbGpPWpGaD
Sulindac—Decreased appetite—Methotrexate—systemic scleroderma	5.67e-05	0.000389	CcSEcCtD
Sulindac—PTGDR2—Signaling Pathways—EDN1—systemic scleroderma	5.67e-05	0.00121	CbGpPWpGaD
Sulindac—Fatigue—Methotrexate—systemic scleroderma	5.62e-05	0.000385	CcSEcCtD
Sulindac—Asthenia—Prednisone—systemic scleroderma	5.6e-05	0.000384	CcSEcCtD
Sulindac—Pruritus—Prednisone—systemic scleroderma	5.52e-05	0.000378	CcSEcCtD
Sulindac—MAPK3—Signaling by GPCR—RHOB—systemic scleroderma	5.39e-05	0.00115	CbGpPWpGaD
Sulindac—MAPK3—Disease—TGFBI—systemic scleroderma	5.38e-05	0.00115	CbGpPWpGaD
Sulindac—Feeling abnormal—Methotrexate—systemic scleroderma	5.37e-05	0.000368	CcSEcCtD
Sulindac—Diarrhoea—Prednisone—systemic scleroderma	5.34e-05	0.000366	CcSEcCtD
Sulindac—PPARD—Metabolism—CTGF—systemic scleroderma	5.33e-05	0.00114	CbGpPWpGaD
Sulindac—Gastrointestinal pain—Methotrexate—systemic scleroderma	5.33e-05	0.000366	CcSEcCtD
Sulindac—Urticaria—Methotrexate—systemic scleroderma	5.18e-05	0.000355	CcSEcCtD
Sulindac—Dizziness—Prednisone—systemic scleroderma	5.16e-05	0.000354	CcSEcCtD
Sulindac—Body temperature increased—Methotrexate—systemic scleroderma	5.15e-05	0.000353	CcSEcCtD
Sulindac—Vomiting—Prednisone—systemic scleroderma	4.96e-05	0.00034	CcSEcCtD
Sulindac—Rash—Prednisone—systemic scleroderma	4.92e-05	0.000337	CcSEcCtD
Sulindac—Dermatitis—Prednisone—systemic scleroderma	4.92e-05	0.000337	CcSEcCtD
Sulindac—Headache—Prednisone—systemic scleroderma	4.89e-05	0.000335	CcSEcCtD
Sulindac—ALB—Selenium Micronutrient Network—IL1B—systemic scleroderma	4.85e-05	0.00104	CbGpPWpGaD
Sulindac—ALB—Hemostasis—SELP—systemic scleroderma	4.84e-05	0.00103	CbGpPWpGaD
Sulindac—Hypersensitivity—Methotrexate—systemic scleroderma	4.8e-05	0.000329	CcSEcCtD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	4.8e-05	0.00102	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—IL1B—systemic scleroderma	4.74e-05	0.00101	CbGpPWpGaD
Sulindac—Asthenia—Methotrexate—systemic scleroderma	4.68e-05	0.000321	CcSEcCtD
Sulindac—MAPK3—MAPK Signaling Pathway—TGFB1—systemic scleroderma	4.67e-05	0.000998	CbGpPWpGaD
Sulindac—Nausea—Prednisone—systemic scleroderma	4.63e-05	0.000318	CcSEcCtD
Sulindac—Pruritus—Methotrexate—systemic scleroderma	4.61e-05	0.000316	CcSEcCtD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	4.58e-05	0.000979	CbGpPWpGaD
Sulindac—ALB—Hemostasis—RHOB—systemic scleroderma	4.52e-05	0.000966	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CSK—systemic scleroderma	4.49e-05	0.000959	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—MMP9—systemic scleroderma	4.47e-05	0.000955	CbGpPWpGaD
Sulindac—Diarrhoea—Methotrexate—systemic scleroderma	4.46e-05	0.000306	CcSEcCtD
Sulindac—MAPK3—Axon guidance—MMP2—systemic scleroderma	4.46e-05	0.000952	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	4.43e-05	0.000946	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IRF5—systemic scleroderma	4.42e-05	0.000943	CbGpPWpGaD
Sulindac—Dizziness—Methotrexate—systemic scleroderma	4.31e-05	0.000296	CcSEcCtD
Sulindac—MAPK3—Disease—HSPG2—systemic scleroderma	4.29e-05	0.000917	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	4.26e-05	0.00091	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IRF8—systemic scleroderma	4.22e-05	0.000901	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CD247—systemic scleroderma	4.22e-05	0.000901	CbGpPWpGaD
Sulindac—MAPK3—Immune System—ITGAM—systemic scleroderma	4.22e-05	0.000901	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	4.21e-05	0.0009	CbGpPWpGaD
Sulindac—Vomiting—Methotrexate—systemic scleroderma	4.15e-05	0.000284	CcSEcCtD
Sulindac—MAPK3—Disease—CSK—systemic scleroderma	4.14e-05	0.000885	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—SMAD7—systemic scleroderma	4.12e-05	0.00088	CbGpPWpGaD
Sulindac—ALB—Hemostasis—CSK—systemic scleroderma	4.12e-05	0.00088	CbGpPWpGaD
Sulindac—Rash—Methotrexate—systemic scleroderma	4.11e-05	0.000282	CcSEcCtD
Sulindac—Dermatitis—Methotrexate—systemic scleroderma	4.11e-05	0.000282	CcSEcCtD
Sulindac—Headache—Methotrexate—systemic scleroderma	4.09e-05	0.00028	CcSEcCtD
Sulindac—ALB—Platelet degranulation—TGFB1—systemic scleroderma	4.07e-05	0.000869	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—MMP1—systemic scleroderma	4.03e-05	0.000861	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—IL1B—systemic scleroderma	3.99e-05	0.000853	CbGpPWpGaD
Sulindac—MAPK3—Immune System—TNFAIP3—systemic scleroderma	3.95e-05	0.000844	CbGpPWpGaD
Sulindac—MAPK3—Immune System—BLK—systemic scleroderma	3.9e-05	0.000834	CbGpPWpGaD
Sulindac—MAPK3—Disease—CD247—systemic scleroderma	3.9e-05	0.000832	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	3.88e-05	0.000829	CbGpPWpGaD
Sulindac—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—systemic scleroderma	3.88e-05	0.000828	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—CCL2—systemic scleroderma	3.87e-05	0.000828	CbGpPWpGaD
Sulindac—Nausea—Methotrexate—systemic scleroderma	3.87e-05	0.000266	CcSEcCtD
Sulindac—ALB—Hemostasis—ITGAM—systemic scleroderma	3.87e-05	0.000827	CbGpPWpGaD
Sulindac—MAPK3—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	3.75e-05	0.000801	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—TGFB1—systemic scleroderma	3.68e-05	0.000787	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	3.64e-05	0.000777	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—CTGF—systemic scleroderma	3.5e-05	0.000748	CbGpPWpGaD
Sulindac—PTGS2—Disease—SMAD7—systemic scleroderma	3.5e-05	0.000747	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—NOS3—systemic scleroderma	3.45e-05	0.000738	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—MMP9—systemic scleroderma	3.35e-05	0.000716	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	3.23e-05	0.000689	CbGpPWpGaD
Sulindac—PTGS2—Disease—TGFBI—systemic scleroderma	3.2e-05	0.000683	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CTLA4—systemic scleroderma	3.2e-05	0.000683	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—RHOB—systemic scleroderma	3.19e-05	0.000681	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—MMP2—systemic scleroderma	3.18e-05	0.00068	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—HSPG2—systemic scleroderma	3e-05	0.000642	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	2.94e-05	0.000628	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—NOS3—systemic scleroderma	2.92e-05	0.000625	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CSK—systemic scleroderma	2.9e-05	0.00062	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—MMP9—systemic scleroderma	2.77e-05	0.000592	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—EDN1—systemic scleroderma	2.75e-05	0.000588	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	2.72e-05	0.00058	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—HSPG2—systemic scleroderma	2.69e-05	0.000575	CbGpPWpGaD
Sulindac—MAPK3—Immune System—HLA-DQB1—systemic scleroderma	2.63e-05	0.000563	CbGpPWpGaD
Sulindac—PTGS2—Disease—HSPG2—systemic scleroderma	2.55e-05	0.000545	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	2.51e-05	0.000535	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IL1A—systemic scleroderma	2.5e-05	0.000534	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CD40LG—systemic scleroderma	2.49e-05	0.000531	CbGpPWpGaD
Sulindac—PTGS2—Disease—CSK—systemic scleroderma	2.46e-05	0.000526	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—MMP9—systemic scleroderma	2.39e-05	0.000511	CbGpPWpGaD
Sulindac—PPARD—Metabolism—NOS3—systemic scleroderma	2.32e-05	0.000496	CbGpPWpGaD
Sulindac—PTGS2—Disease—CD247—systemic scleroderma	2.32e-05	0.000495	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—TGFB1—systemic scleroderma	2.28e-05	0.000488	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—HSPG2—systemic scleroderma	2.14e-05	0.000456	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	2.06e-05	0.00044	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—CTGF—systemic scleroderma	2.04e-05	0.000436	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—TGFB1—systemic scleroderma	1.97e-05	0.000421	CbGpPWpGaD
Sulindac—ALB—Hemostasis—MMP1—systemic scleroderma	1.94e-05	0.000414	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—TGFB1—systemic scleroderma	1.93e-05	0.000413	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—HSPG2—systemic scleroderma	1.9e-05	0.000405	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—CCL2—systemic scleroderma	1.88e-05	0.000402	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	1.8e-05	0.000385	CbGpPWpGaD
Sulindac—ALB—Metabolism—HSPG2—systemic scleroderma	1.73e-05	0.000369	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—EDN1—systemic scleroderma	1.63e-05	0.000347	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—CTGF—systemic scleroderma	1.62e-05	0.000346	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—CTGF—systemic scleroderma	1.44e-05	0.000307	CbGpPWpGaD
Sulindac—MAPK3—Disease—NOS3—systemic scleroderma	1.42e-05	0.000302	CbGpPWpGaD
Sulindac—ALB—Hemostasis—NOS3—systemic scleroderma	1.41e-05	0.0003	CbGpPWpGaD
Sulindac—ALB—Metabolism—CTGF—systemic scleroderma	1.31e-05	0.00028	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IL1B—systemic scleroderma	1.3e-05	0.000279	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—HSPG2—systemic scleroderma	1.21e-05	0.000258	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CCL2—systemic scleroderma	1.11e-05	0.000238	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—NOS3—systemic scleroderma	9.91e-06	0.000212	CbGpPWpGaD
Sulindac—MAPK3—Disease—TGFB1—systemic scleroderma	9.36e-06	0.0002	CbGpPWpGaD
Sulindac—ALB—Hemostasis—TGFB1—systemic scleroderma	9.3e-06	0.000199	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CTGF—systemic scleroderma	9.16e-06	0.000196	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—NOS3—systemic scleroderma	8.88e-06	0.00019	CbGpPWpGaD
Sulindac—PTGS2—Disease—NOS3—systemic scleroderma	8.42e-06	0.00018	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MMP9—systemic scleroderma	7.95e-06	0.00017	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—NOS3—systemic scleroderma	7.05e-06	0.000151	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TGFB1—systemic scleroderma	6.55e-06	0.00014	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—NOS3—systemic scleroderma	6.26e-06	0.000134	CbGpPWpGaD
Sulindac—ALB—Metabolism—NOS3—systemic scleroderma	5.7e-06	0.000122	CbGpPWpGaD
Sulindac—PTGS2—Disease—TGFB1—systemic scleroderma	5.57e-06	0.000119	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—NOS3—systemic scleroderma	3.99e-06	8.52e-05	CbGpPWpGaD
